Pharmacoeconomic Guidelines: Guatemala
Country/Region: Guatemala
Submission Guidelines
Manual of Standards and Procedures for Health Technology Assessment of Medications
Submission Guidelines Source:
Additional Information:
Information current as of Thursday, February 22, 2024
Key Features
| Key Features | |
|---|---|
| Type of Guidelines | Submission Guidelines |
| Title and year of the document | Manual of Standards and Procedures for Health Technology Assessment of Medications (Nov 2021) |
| Affiliation of authors | Arturo Ernesto Garcia (Health Services Deputy Management, Social Security Institute of Guatemala) |
| Purpose of the document | The manual aims to provide an administrative tool to regulate the administrative and operational management conducted by the Department of Pharmacotherapy of the Central Therapeutic Directorate in the health technology assessment for the inclusion, modification, or exclusion of drugs from the Institute's Basic Drug List. It also aims to inform the human resources of the Department of Pharmacotherapy about their responsibilities in carrying out activities related to the assessment of health technologies for the inclusion, modification, or exclusion of drugs from the Basic Drug List. |
| Standard reporting format included | Yes (Annex 1) |
| Disclosure | Yes (Annex 2) |
| Target audience of funding/ author's interests | Pharmacotherapy Department, Social Security Institute of Guatemala |
| Perspective | Public healthcare system perspective |
| Indication | Yes. |
| Target population | Yes. |
| Subgroup analysis | Not stated. |
| Choice of comparator | Other therapies for the same indication. |
| Time horizon | Not defined. |
| Assumptions required | Not defined. |
| Preferred analytical technique | Not defined. |
| Costs to be included | Unitary price. |
| Source of costs | Not defined. |
| Modeling | Not defined. |
| Systematic review of evidences | At least: 1 meta-analysis, 1 systematic review, and 1 evidence-based practical guideline. All three must be at least 5 years old. |
| Preference for effectiveness over efficacy | Not defined. |
| Preferred outcome measure | Not defined. |
| Preferred method to derive utility | Not defined. |
| Equity issues stated | No. |
| Discounting costs | Not defined. |
| Discounting outcomes | No. |
| Sensitivity analysis-parameters and range | Not defined. |
| Sensitivity analysis-methods | Not defined. |
| Presenting results | Free text. |
| Incremental analysis | No. |
| Total costs vs effectiveness (cost/effectiveness ratio) | No. |
| Portability of results (Generalizability) | Not defined. |
| Financial impact analysis | At the discretion of the Department Pharmacoeconomist in charge. |
| Mandatory or recommended or voluntary | Not defined. |
Acknowledgement: